These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777 [TBL] [Abstract][Full Text] [Related]
4. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010 [TBL] [Abstract][Full Text] [Related]
5. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM; J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495 [TBL] [Abstract][Full Text] [Related]
6. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults. Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476 [TBL] [Abstract][Full Text] [Related]
7. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease. Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314 [TBL] [Abstract][Full Text] [Related]
8. Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease. Inekci D; Henriksen K; Linemann T; Karsdal MA; Habib A; Bisgaard C; Eriksen FB; Vilholm OJ Curr Alzheimer Res; 2015; 12(9):829-36. PubMed ID: 26159200 [TBL] [Abstract][Full Text] [Related]
9. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia. Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536 [TBL] [Abstract][Full Text] [Related]
10. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease. Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478 [TBL] [Abstract][Full Text] [Related]
11. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545 [TBL] [Abstract][Full Text] [Related]
12. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers. Khoonsari PE; Shevchenko G; Herman S; Remnestål J; Giedraitis V; Brundin R; Degerman Gunnarsson M; Kilander L; Zetterberg H; Nilsson P; Lannfelt L; Ingelsson M; Kultima K J Alzheimers Dis; 2019; 67(2):639-651. PubMed ID: 30614806 [TBL] [Abstract][Full Text] [Related]
14. Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression. Jahn T; Clark C; Kerksiek A; Lewczuk P; Lütjohann D; Popp J J Steroid Biochem Mol Biol; 2021 Jan; 205():105785. PubMed ID: 33171206 [TBL] [Abstract][Full Text] [Related]
15. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease. Hohman TJ; Bell SP; Jefferson AL; JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166 [TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population. Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262 [TBL] [Abstract][Full Text] [Related]
17. Clinical indications for analysis of Alzheimer's disease CSF biomarkers. Engelborghs S Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466 [TBL] [Abstract][Full Text] [Related]
18. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097 [TBL] [Abstract][Full Text] [Related]
19. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR; Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049 [TBL] [Abstract][Full Text] [Related]
20. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Vemuri P; Wiste HJ; Weigand SD; Knopman DS; Trojanowski JQ; Shaw LM; Bernstein MA; Aisen PS; Weiner M; Petersen RC; Jack CR; Neurology; 2010 Jul; 75(2):143-51. PubMed ID: 20625167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]